News
FDA still sceptical about Intercept’s NASH drug
Intercept Pharma’s hope that its OCA candidate could become the first FDA-approved drug to treat non-alcoholic steatohepatitis (NASH) is starting to look decidedly faint.
Friday 6 February 2026
